--- title: 'Funding Daily Summary: What Happened on October 18, 2026' headline: OMass raises $310 million for endocrine and immunology drugs description: The Series C backs Phase 2 plans for OMS1620 and earlier work on a potential lupus drug. url: https://thebench.bio/news/funding/2026-10-18 topic: funding date: '2026-10-18' covers: - '2026-10-18' date_published: '2026-10-19T00:00:16Z' date_modified: '2026-10-19T00:00:16Z' tags: - Industry sources: 1 publisher: TheBench.Bio --- # Funding Daily Summary: What Happened on October 18, 2026 **OMass raises $310 million for endocrine and immunology drugs** The Series C backs Phase 2 plans for OMS1620 and earlier work on a potential lupus drug. ## Today in brief OMass Therapeutics raised $310 million to advance OMS1620, which it plans to take into Phase 2 testing for two endocrine disorders. [1] The company will also fund earlier research, including a potential SLC15A4 inhibitor for lupus. [1] ## OMass raises $310 million for endocrine and immunology programs OMass announced the Series C on October 15, with Bain Capital Life Sciences, Forbion and Novo Holdings joining as co-leaders and new investors. [1] The company plans to advance OMS1620 through Phase 2 testing for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. [1] OMass says OMS1620 is designed to bind its target receptor for longer and stay active as hormone levels rise. [1] The company says these properties could help more patients reach hormone levels closer to normal while taking glucocorticoids. [1] The financing will also support earlier programs, including a potential first-in-class SLC15A4 inhibitor for lupus and other conditions linked to excess interferon production and harmful B-cell activation. [1] The FDA approved Crenessity in 2024, and it is currently the only available drug for congenital adrenal hyperplasia. [1] Neurocrine reported $301.2 million in Crenessity sales for 2025. [1] Vertex is also pursuing the market with atumelnant, which came from its acquisition of Crinetics Pharmaceuticals. [1] ## The day in numbers - **$310 million**: OMass Therapeutics’ Series C financing [1] ## Sources 1. [Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder](), MedCity News, 2026-10-18 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: